Press Releases :: BiomX, Inc. (PHGE)

Feb 02, 2021 6:30am EST

BiomX Announces Positive Results of a Phase 1a Pharmacokinetic Study for Inflammatory Bowel Disease/Primary Sclerosing Cholangitis (IBD/PSC) Evaluating Delivery of Oral BX002 Phage Therapy

Jan 04, 2021 6:30am EST

BiomX to Present at Upcoming January Investor Conferences

Dec 09, 2020 4:30pm EST

BiomX Announces Preclinical Results of Analysis of Patient Samples and Engineering of Phage for Therapeutic Applications in Colorectal Cancer

Nov 16, 2020 6:30am EST

BiomX Presents Preclinical Results of Phage Targeting Klebsiella pneumoniae for Primary Sclerosing Cholangitis and Inflammatory Bowel Disease

Nov 12, 2020 6:30am EST

BiomX Reports Third Quarter 2020 Financial Results and Announces Expanded Portfolio of Phage Therapy Candidates

Nov 10, 2020 4:30pm EST

BiomX to Present at Upcoming November Investor Conferences

Nov 05, 2020 6:30am EST

BiomX to Report Third Quarter 2020 Financial Results on Nov. 12, 2020

Nov 04, 2020 6:30am EST

BiomX Announces Dosing of First Subject in Phase 1a Study of BX002 Phage Therapy for Inflammatory Bowel Disease

Oct 21, 2020 6:30am EDT

BiomX Presents Preclinical Data on Phage Targeting Multidrug Resistant Klebsiella pneumoniae Bacteria at the Infectious Disease Society of America (IDSA) IDWeek Conference 2020

Oct 05, 2020 6:30am EDT

BiomX Appoints Paul Sekhri and Alan Moses, M.D., to Board of Directors

Previous
1…
4
5
6
7
8
9
10
11
12
13
Next

Investor Contact Information

Company

BiomX, Inc.
708 Quince Orchard Rd
Suite 205
Gaithersburg, MD 20878
USA
info@biomx.com

Investor Relations

Ben Cohen
benc@biomx.com